ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
13 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
During aging, the central nervous system (“CNS”) becomes more inflammatory, leading to activation of microglia (“CNS immune cells”), tissue damage, dysfunction, and senescenceThe article reviews...
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
12 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Mr. Glover will participate in a live interview on Benzinga All Access on April 18, 2023, to discuss the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, for renal...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
11 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Mr. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS...
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
10 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...
ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
03 avr. 2023 09h05 HE
|
ZyVersa Therapeutics
Key Highlights: Closed business combination with Larkspur Health Acquisition Corp. in December 2022 and began trading on Nasdaq Global Market under the ticker symbol “ZVSA”Planning underway with...
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 mars 2023 16h30 HE
|
ZyVersa Therapeutics
WESTON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200
07 mars 2023 09h20 HE
|
ZyVersa Therapeutics
Cholesterol Efflux Mediator VAR 200 is a phase 2a-ready drug in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to progression of kidney disease...
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
01 mars 2023 09h20 HE
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
27 févr. 2023 09h20 HE
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which...
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
23 févr. 2023 09h20 HE
|
ZyVersa Therapeutics
Data published in Translational Research indicate that pyroptotic release of cytokines and ASC Specks from traumatic brain injury (TBI) induces a heightened inflammasome response in Alzheimer’s...